Literature DB >> 21346852

Response-guided therapy for HCV.

Paul Y Kwo1.   

Abstract

Year:  2011        PMID： 21346852      PMCID： PMC3038316     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  4 in total

1.  Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy.

Authors:  Donald M Jensen; Timothy R Morgan; Patrick Marcellin; Paul J Pockros; K Rajender Reddy; Stephanos J Hadziyannis; Peter Ferenci; Andrew M Ackrill; Bernard Willems
Journal:  Hepatology       Date:  2006-05       Impact factor: 17.425

2.  Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.

Authors:  Alessandra Mangia; Rosanna Santoro; Nicola Minerva; Giovanni L Ricci; Vito Carretta; Marcello Persico; Francesco Vinelli; Gaetano Scotto; Donato Bacca; Mauro Annese; Mario Romano; Franco Zechini; Fernando Sogari; Fulvio Spirito; Angelo Andriulli
Journal:  N Engl J Med       Date:  2005-06-23       Impact factor: 91.245

3.  Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.

Authors:  Thomas Berg; Michael von Wagner; Samer Nasser; Christoph Sarrazin; Tobias Heintges; Tilman Gerlach; Peter Buggisch; Tobias Goeser; Jens Rasenack; Gerd R Pape; Wolfgang E Schmidt; Birgit Kallinowski; Hartwig Klinker; Ulrich Spengler; Peter Martus; Ulrich Alshuth; Stefan Zeuzem
Journal:  Gastroenterology       Date:  2006-04       Impact factor: 22.682

Review 4.  Optimizing the treatment of chronic hepatitis due to hepatitis C virus genotypes 2 and 3: a review.

Authors:  Giuseppe Tarantino; Antonio Craxì
Journal:  Liver Int       Date:  2009-01       Impact factor: 5.828
  4 in total
  1 in total

1.  Simeprevir with peginterferon and ribavirin induced interstitial pneumonitis: first case report.

Authors:  Katsuyoshi Tamaki; Akihiko Okubo
Journal:  World J Gastroenterol       Date:  2015-01-21       Impact factor: 5.742
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.